There is a growing body of evidence more conclusively demonstrating the medical benefits of cannabis. Yet, the full potential of these products are not being realized in part because of a lack of rigorous clinical evidence and careful consideration of product attributes that can distinguish specific cannabis-based pharmaceuticals.

The panel will discuss what the industry can do to further shift the sentiment among the medical community and patients and ultimately deliver enhanced health benefits.

Speakers:

• David Berg, President and Chief Technology Officer at Strainprint
• Chris Delvecchio, Principal, Shift Health
• Jeremey Desai, Director and CEO of Madara Pharma